Eulambius M. Mlugu

Eulambius M. Mlugu

Auto-generated profile, based on publicly available information

Eulambius M. Mlugu

Division of Clinical Pharmacology Department of Laboratory Medicine Karolinska Institutet at Karolinska University Hospital Stockholm Sweden

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
EMEulambius M. Mlugu
Eulambius M. Mlugu
OMOmary Mashiku Minzi
Omary Mashiku Minzi
AKAppolinary A. R. Kamuhabwa
Appolinary A. R. Kamuhabwa
EAEleni Aklillu
Eleni Aklillu
Intermittent preventive treatment in pregnancy with sulfadoxine‐pyrimethamine (IPTp‐SP) to prevent malaria and adverse birth outcomes is threatened by Plasmodium falciparum resistance to sulfadoxine‐pyrimethamine. We investigated the effectiveness of intermittent preventive treatment in pregnancy with monthly dihydroartemisinin‐piperaquine (IPTp‐DHP) as an alternative option to IPTp‐SP. A total of 956 malaria‐free (malaria rapid diagnostic test (MRDT) negative) pregnant women from moderate malaria transmission areas in Tanzania were enrolled and randomized to receive monthly IPTp‐DHP (n = 478) or IPTp‐SP (n = 478) and followed for maternal and birth outcomes. The primary outcome was the prevalence of histopathologically confirmed placental malaria (active or past infection). Secondary outcomes were overall malaria at delivery, symptomatic‐malaria, parasitemia during pregnancy, and adverse birth outcomes as a composite of spontaneous‐abortion, premature birth, stillbirth, and low birth weight (LBW) fetal anemia. Outcome differences between treatment groups were expressed as the protective efficacy (PE), defined as 1‐prevalence ratios or 1‐incidence rate ratio. The prevalence of histopathologically confirmed placental malaria was significantly lower in IPTp‐DHP (2.5%, 12/478) than IPTp‐SP (8.2%, 39/478); PE = 69% (95% confidence interval (CI): 42–84, P < 0.001). The prevalence of maternal malaria at delivery was significantly lower in IPTp‐DHP (8.2%) than IPTp‐SP (18.2%, P < 0.001). The incidence per person‐years at risk for symptomatic‐malaria (0.02 vs. 0.12, P = 0.002) and parasitemia during pregnancy (0.28 vs. 0.67, P < 0.001) were significantly lower in the IPTp‐DHP group than in the IPTp‐SP group. The prevalence of any adverse birth outcomes (composite) was not significantly (P = 0.06) different between IPTp‐DHP (17.9%) and IPTp‐SP (23.8%). However, the prevalence of LBW (4.6% vs. 9.6%, P = 0.003) was significantly lower in IPTp‐DHP compared with IPTp‐SP. We report superior protective efficacy of monthly IPTp‐DHP against malaria in pregnancy and LBW than IPTp‐SP.